Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features
- PMID: 22405656
- PMCID: PMC3374916
- DOI: 10.1016/j.psychres.2011.08.014
Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features
Erratum in
- Psychiatry Res. 2013 Dec 30;210(3):1329
Abstract
Newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis appear to have increases in pro-inflammatory cytokines. Patients characterized by primary, enduring negative symptoms (deficit symptoms) differ from patients without such features with regard to course of illness, treatment response, risk factors and metabolic disturbances. We hypothesized that they would also differ on concentrations of the inflammatory markers interleukin-6 (IL6) and C-reactive protein (CRP). Newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis were categorized into deficit (N=20) and nondeficit (N=42) groups, and were matched on age, gender, body mass index, smoking, cortisol level, socioeconomic status, and the severity of psychotic symptoms. Fasting concentrations of IL6 were significantly higher in deficit (mean [S.D.]) (8.0 pg/ml [12.7]) than nondeficit patients (0.3 pg/ml [1.3]). CRP levels were also significantly higher in the deficit patients (0.3 mg/dl [0.4]) vs. (0.2 mg/dl [0.4]), respectively. In contrast, 2-h glucose concentrations (2HG) in a glucose tolerance test were lower in the deficit than the nondeficit group. Our results show a double dissociation with regard to glucose intolerance and inflammation: the deficit group has greater inflammation, but less severe glucose intolerance. These results provide further evidence for the validity of the deficit/nondeficit categorization.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Differences in glucose tolerance between deficit and nondeficit schizophrenia.Schizophr Res. 2009 Feb;107(2-3):122-7. doi: 10.1016/j.schres.2008.09.023. Epub 2008 Nov 28. Schizophr Res. 2009. PMID: 19046857 Free PMC article.
-
Metabolic profile of antipsychotic-naive individuals with non-affective psychosis.Br J Psychiatry. 2009 May;194(5):434-8. doi: 10.1192/bjp.bp.108.052605. Br J Psychiatry. 2009. PMID: 19407273 Free PMC article.
-
Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?Schizophr Bull. 2012 Mar;38(2):280-4. doi: 10.1093/schbul/sbq058. Epub 2010 Jun 17. Schizophr Bull. 2012. PMID: 20558532 Free PMC article.
-
Impaired insight in patients with newly diagnosed nonaffective psychotic disorders with and without deficit features.Schizophr Res. 2011 Mar;126(1-3):252-6. doi: 10.1016/j.schres.2010.08.024. Schizophr Res. 2011. PMID: 20817414 Free PMC article.
-
Meta-analysis of glucose tolerance, insulin, and insulin resistance in antipsychotic-naïve patients with nonaffective psychosis.Schizophr Res. 2017 Jan;179:57-63. doi: 10.1016/j.schres.2016.09.026. Epub 2016 Oct 17. Schizophr Res. 2017. PMID: 27743650 Free PMC article. Review.
Cited by
-
The aetiology of social deficits within mental health disorders: The role of the immune system and endogenous opioids.Brain Behav Immun Health. 2019 Nov 14;1:100003. doi: 10.1016/j.bbih.2019.100003. eCollection 2020 Jan. Brain Behav Immun Health. 2019. PMID: 38377411 Free PMC article. Review.
-
Network analysis of inflammation and symptoms in recent onset schizophrenia and the influence of minocycline during a clinical trial.Transl Psychiatry. 2023 Sep 18;13(1):297. doi: 10.1038/s41398-023-02570-8. Transl Psychiatry. 2023. PMID: 37723153 Free PMC article.
-
Predictors of successful anti-inflammatory drug trials in patients with schizophrenia: A meta-regression and critical commentary.Brain Behav Immun. 2023 Nov;114:154-162. doi: 10.1016/j.bbi.2023.08.001. Epub 2023 Aug 20. Brain Behav Immun. 2023. PMID: 37607662
-
A study of the association between polymorphisms in the genes for interleukins IL-6 and IL-10 and negative symptoms subdomains in schizophrenia.Indian J Psychiatry. 2022 Sep-Oct;64(5):484-488. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_212_22. Epub 2022 Oct 12. Indian J Psychiatry. 2022. PMID: 36458089 Free PMC article.
-
Differences in inflammatory marker profiles and cognitive functioning between deficit and nondeficit schizophrenia.Front Immunol. 2022 Oct 19;13:958972. doi: 10.3389/fimmu.2022.958972. eCollection 2022. Front Immunol. 2022. PMID: 36341400 Free PMC article.
References
-
- Addington J, Saeedi H, Addington D. The course of cognitive functioning in first episode psychosis: changes over time and impact on outcome. Schizophr Research. 2005;78:35–43. - PubMed
-
- Akanji AO, Ohaeri JU, Al-Shammri S, Fatania HR. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Research. 2009;169:56–61. - PubMed
-
- Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophrenia Research. 1999;37:97–106. - PubMed
-
- Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research. 2007;90:179–185. - PubMed
-
- Arango C, Bobes J, Kirkpatrick B, Garcia-Garcia M, Rejas J. Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the CLAMORS study. European Neuropsychopharmacology 2011 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
